Every treatment we prescribe is backed by peer-reviewed clinical trials and NICE guidance. Explore the evidence across all 6 condition areas — 65 treatments, 35 conditions.
Medically Supervised Weight Management
Obesity is a complex, chronic disease — not a lifestyle choice. It is driven by powerful hormonal, genetic and neurological signals that override willpower. GLP-1 receptor agonists (such as semaglutide and tirzepatide) work with your biology, not against it, by modulating the hormones that control hunger, satiety and blood glucose.
Avg % Body Weight Lost (72 weeks)
Weight loss over time (Weeks)
Patients ≥5% loss
Mounjaro® (Tirzepatide)
Dual GIP/GLP-1 Receptor Agonist · Injectable — once weekly
22.5% mean body weight reduction at 72 weeks (SURMOUNT-1). 64% achieved ≥15% weight loss at highest dose.
SURMOUNT-1 (NEJM 2022); NICE TA875 (2023) · NICE TA875 (2023) · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · SPS Tirzepatide guidance · MHRA Drug Safety Update (GLP-1 RAs)
Wegovy® (Semaglutide 2.4mg)
GLP-1 Receptor Agonist · Injectable — once weekly
20.7% mean weight reduction at 72 weeks (STEP 1). 86% of participants lost ≥5% body weight.
STEP 1 (NEJM 2021); NICE TA875 (2023) · NICE TA875 (2023) · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · SPS Semaglutide (Wegovy®) guidance · MHRA Drug Safety Update (GLP-1 RAs)
Wegovy® Pill (Oral Semaglutide 25mg)
GLP-1 Receptor Agonist — Oral Formulation · Oral tablet — once daily
13.6% mean body weight reduction at 64 weeks (OASIS-4). 76% achieved ≥5% weight loss vs 31% on placebo. First oral GLP-1 approved for chronic weight management.
OASIS-4 (NEJM 2025); SELECT cardiovascular outcomes trial; first oral GLP-1 for weight loss · NICE TA1085 (2025, oral semaglutide) · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · SPS Oral semaglutide guidance · MHRA Drug Safety Update (GLP-1 RAs)
Saxenda® (Liraglutide)
GLP-1 Receptor Agonist · Injectable — once daily
Average 8% body weight loss at 56 weeks (SCALE trial) alongside diet and exercise. Maintenance of weight loss in most patients at 1 year on the 3mg dose.
SCALE (NEJM 2015); NICE TA661 (2022) · NICE TA661 (2022, liraglutide 3mg) · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · SPS Liraglutide guidance · MHRA Drug Safety Update (GLP-1 RAs)
Orlistat 120mg (Xenical® / Generic)
Pancreatic Lipase Inhibitor · Oral capsule — 3× daily with meals
Average 5.8kg additional weight loss vs placebo at 1 year. Reduces cardiovascular risk factors and delays onset of Type 2 Diabetes.
NICE CG189 (2014 updated 2023); XENDOS trial · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · NICE CG189 (2014, updated 2023) · BNF Orlistat · SPS Orlistat interactions guidance
Foundayo™ (Orforglipron)
Oral GLP-1 Receptor Agonist — small molecule · Oral tablet — once daily
12.4% mean body weight reduction at 72 weeks (ATTAIN-1) at the maximum dose alongside lifestyle changes.
ATTAIN-1 (2025); orforglipron Phase 3, Eli Lilly · NPA Pharmacist Independent Prescriber Guidance · GPhC Guidance for Pharmacist Prescribers · GPhC Standards for Pharmacy Professionals · ATTAIN-1 trial · MHRA licensed (2026) · SPS GLP-1 guidance · MHRA (GLP-1 RAs)
All cited evidence in Weight Loss Clinic (12)
50,000+
Registered Patients
204,000+
Prescriptions Issued
1,000,000+
NHS Prescription Items Delivered
98%
Patient Satisfaction
We use essential cookies to run our site, and — with your consent — analytics cookies to understand how it's used. See our Cookie Policy.